Teva Pharmaceutical Industries LimitedTEVANYSE
Loading
Book Value/Share Growth AcceleratingAccelerating
Percentile Rank97
5Y CAGR+16.8%
Year-over-Year Change
Year-over-year book value per share growth
5Y CAGR
+16.8%/yr
Long-term compound
Percentile
P97
Near historical high
vs 5Y Ago
2.2x
Strong expansion
Streak
1 qtr
Consecutive growthAccelerating
| Period | Value |
|---|---|
| Q4 2025 | 8.89% |
| Q3 2025 | 6.15% |
| Q2 2025 | 8.16% |
| Q1 2025 | 9.12% |
| Q4 2024 | -10.40% |
| Q3 2024 | -2.73% |
| Q2 2024 | -13.76% |
| Q1 2024 | -7.34% |
| Q4 2023 | 8.19% |
| Q3 2023 | -2.64% |
| Q2 2023 | -10.89% |
| Q1 2023 | -0.21% |
| Q4 2022 | -9.67% |
| Q3 2022 | -3.24% |
| Q2 2022 | -4.47% |
| Q1 2022 | -9.08% |
| Q4 2021 | -1.81% |
| Q3 2021 | 1.24% |
| Q2 2021 | 2.69% |
| Q1 2021 | -0.78% |
| Q4 2020 | 4.09% |
| Q3 2020 | -28.51% |
| Q2 2020 | 1.34% |
| Q1 2020 | -3.24% |
| Q4 2019 | 0.08% |
| Q3 2019 | -1.30% |
| Q2 2019 | -7.32% |
| Q1 2019 | -1.64% |
| Q4 2018 | -19.05% |
| Q3 2018 | -1.89% |
| Q2 2018 | -2.42% |
| Q1 2018 | 7.24% |
| Q4 2017 | -38.13% |
| Q3 2017 | 2.22% |
| Q2 2017 | -17.17% |
| Q1 2017 | 2.05% |
| Q4 2016 | -8.85% |
| Q3 2016 | 7.95% |
| Q2 2016 | 4.57% |
| Q1 2016 | -3.04% |